Key result
Intracoronary Ad.AC(VI) attenuates LV dP/dt decline versus saline in pigs with heart failure.
Why the study?
The effect of intracoronary delivery of adenovirus encoding adenylyl cyclase type VI on left ventricular function in congestive heart failure was tested.
Does intracoronary delivery of an adenovirus encoding adenylyl cyclase type VI improve left ventricular function in a porcine model of congestive heart failure?
RCT (n=16)
blinded
randomized
Does intracoronary delivery of an adenovirus encoding adenylyl cyclase type VI improve left ventricular function in a porcine model of congestive heart failure?
p-value: p=0.0014
Intracoronary delivery of Ad.AC(VI) increases LV function and attenuates deleterious LV remodeling in a porcine model of pacing-induced heart failure.
Attenuates LV dysfunction in porcine HF; hypothesis-generating for AC(VI) gene therapy, requiring human trials.
BACKGROUND: We tested the hypothesis that intracoronary delivery of an adenovirus encoding adenylyl cyclase type VI (Ad.AC(VI)) would be associated with increased left ventricular (LV) function in pigs with congestive heart failure. METHODS AND RESULTS: Pigs (52+/-6 kg; n=16) underwent placement of pacemakers, LV pressure transducers, and left atrial and aortic catheters. Physiological and echocardiographic studies were obtained from conscious animals 13 days later, and pacing was initiated (220 bpm). Seven days later, measures of LV function were reduced, documenting severe LV dysfunction and dilation. Pigs then received intracoronary Ad.AC(VI) (1.4x10(12) vp; n=7) or saline (PBS; n=9) (randomized, blinded), with concomitant infusion of nitroprusside (50 microg/min, 6.4 minutes) to increase gene transfer. Pacing was continued for 14 days, and final studies were obtained. The a priori key end point was change in LV dP/dt during isoproterenol infusion (pre-Ad.AC(VI) value minus value after 21 days of pacing). Pigs receiving Ad.AC(VI) showed a smaller decrease in both LV +dP/dt (P=0.0014) and LV -dP/dt (P=0.0008). Serial echocardiography showed that Ad.AC(VI) treatment was associated with increased LV function and reduced LV dilation and that end-systolic wall stress was reduced. AC-stimulated cAMP production was increased 1.7-fold in LV samples from Ad.AC(VI)-treated pigs (P=0.006), and B-type natriuretic peptide was reduced (0.035). Gene transfer was confirmed by polymerase chain reaction. CONCLUSIONS: AC(VI) gene transfer increases LV function and attenuates deleterious LV remodeling in congestive heart failure.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2004) conducted an RCT in congestive heart failure (n=16). Intracoronary adenovirus encoding adenylyl cyclase type VI (Ad.AC(VI)) vs. saline (PBS) was evaluated on change in LV dP/dt during isoproterenol infusion (p=0.0014). Intracoronary delivery of Ad.AC(VI) in pigs with heart failure significantly attenuated the decrease in LV +dP/dt (P=0.0014) and LV -dP/dt (P=0.0008) compared to saline.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: